Compare Adaptive Biotechnologies Corp (ADPT) vs Phillips 66 (PSX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Phillips 66 — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Phillips 66 trades at $186.74 (market cap $71.70B). The key difference: Phillips 66 is far larger — about 21.5× Adaptive Biotechnologies Corp's market cap, and Phillips 66 pays a 2.84% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | PSX | |
|---|---|---|
Market Cap | $3.33B | $71.70B |
Sector | Health | Energy |
52-Week High | $22.37 | $188.28 |
52-Week Low | $10.24 | $118.37 |
Enterprise Value | $3.19B | $93.68B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Phillips 66 (PSX) trades at $178.84, up 1.37% with a bullish technical signal and strong analyst consensus. The stock shows improving fundamentals with recent earnings beats, a 3.07% net margin, and attractive valuation at P/E 17.52 and P/S 0.54. Recent news highlights resilience amid softer oil prices, supported by diversified operations and a $1.27 dividend payment.
Outlook remains positive with a $190.38 price target, though risks include refining volatility from Hormuz disruptions and declining revenue trends. The stock offers value through stable cash flow and dividend income, but investors should monitor geopolitical impacts on earnings and energy market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
